Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 650 of 1463 entries
View as:

Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

Phase: N/A Priority: Normal
NCT ID: NCT05447169 Org: User:
Start: 07/10/22 End: 07/01/30 Due: 07/01/31

Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT01223664 Org: User:
Start: 10/31/10 End: 11/30/11 Due: 11/30/12

Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

Phase: N/A Priority: Normal
NCT ID: NCT03663764 Org: User:
Start: 08/13/18 End: 08/31/23 Due: 08/31/24

Systemic Screening for Hereditary Colorectal Cancer in China

Phase: N/A Priority: Normal
NCT ID: NCT03365986 Org: User:
Start: 01/01/18 End: 03/31/18 Due: 03/31/19

Comparison of Traditional Cataract Surgery and Traditional Surgery Combined Triamcinolone Staining

Phase: N/A Priority: Normal
NCT ID: NCT04323982 Org: User:
Start: 03/27/20 End: 03/25/21 Due: 03/25/22

Real-time Artificial Intelligence System for Detecting Multiple Ocular Fundus Lesions by Ultra-widefield Fundus Imaging

Phase: N/A Priority: Normal
NCT ID: NCT04859634 Org: User:
Start: 11/01/20 End: 12/25/22 Due: 12/25/23

Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02786641 Org: User:
Start: 08/31/16 End: 08/31/21 Due: 08/31/22

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC

Phase: N/A Priority: Normal
NCT ID: NCT05780294 Org: User:
Start: 04/01/23 End: 12/01/29 Due: 12/01/30

"Sandwich" Chemotherapy With Radiotherapy in Newly Diagnosed, Stage IE to IIE, ENKTL

Phase: N/A Priority: Normal
NCT ID: NCT02520479 Org: User:
Start: 06/30/13 End: 01/31/18 Due: 01/31/19

Postoperative Music for Orbital Decompression

Phase: N/A Priority: Normal
NCT ID: NCT04933201 Org: User:
Start: 06/16/21 End: 12/31/22 Due: 12/31/23

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03837808 Org: User:
Start: 04/11/19 End: 02/11/24 Due: 02/11/25

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04172805 Org: User:
Start: 03/13/20 End: 05/15/24 Due: 05/15/25

Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients

Phase: N/A Priority: Normal
NCT ID: NCT03002064 Org: User:
Start: 12/31/16 End: 12/31/20 Due: 12/31/21

Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04380480 Org: User:
Start: 02/01/20 End: 03/15/22 Due: 03/15/23

TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05220020 Org: User:
Start: 05/18/22 End: 02/28/25 Due: 02/28/26

A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00705627 Org: User:
Start: 06/30/08 End: 06/30/17 Due: 06/30/18

Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01833299 Org: User:
Start: 01/31/10 End: 12/31/18 Due: 12/31/19

Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)

Phase: N/A Priority: Normal
NCT ID: NCT06090656 Org: User:
Start: 03/02/23 End: 07/25/25 Due: 07/25/26

Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05616377 Org: User:
Start: 11/20/22 End: 11/20/24 Due: 11/20/25

The Healthy Cantonese Diet on Cardiometabolic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04064281 Org: User:
Start: 09/01/19 End: 12/31/22 Due: 12/31/23

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06662877 Org: User:
Start: 11/25/24 End: 09/01/29 Due: 09/01/30

Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02861690 Org: User:
Start: 01/31/10 End: 01/31/16 Due: 01/31/17

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03906058 Org: User:
Start: 04/29/19 End: 04/30/22 Due: 04/30/23

CAR-T Cell Immunotherapy for Advanced Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03330834 Org: User:
Start: 11/20/17 End: 04/14/20 Due: 04/14/21

577nm Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT02406157 Org: User:
Start: 01/31/15 End: 07/31/18 Due: 07/31/19